Skip to main content
OpenTrials
Completed

NCT Number: NCT02974816

Glooko mHealth Advantage Study

The purpose of this study is to compare HbA1c of insulin-treated subjects with type 2 diabetes managed via usual care alone and usual care augmented with remote monitoring using Glooko

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

John Muir Physician Network Clinical Research Center, Concord, California, United States

Loading trial locations.

About this study

In this study, the investigator wants to evaluate if diabetes self-management supported by a mobile application, which captures a subject's blood glucose readings, lifestyle and medication information and shares it with the subject's certified diabetes educator (CDE) to enable remote monitoring, improves their glycemic control compared to standard of care.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject has voluntarily signed and dated an informed consent form, approved by an Institutional Review Board/Independent Ethics Committee, and provided Health Insurance Portability and Accountability Act (HIPAA) or other privacy authorization prior to any participation in study.
  • Subject has self-reported type 2 diabetes.
  • Subject has HbA1c ≥ 7.5% and ≤ 12.5% measured within 30 days of screening visit.
  • Subject is on a stable diabetes therapeutic regimen of two or more diabetic medications (e.g., metformin plus one other antihyperglycemic agent) and/or insulin therapy for at least 2 months before screening visit. Dose changes or adjustments made within 2 months is acceptable as long as the patient has been on the medication regimen for 2 months or longer.
  • Subject is ≥ 18 and ≤ 75 years of age.
  • Subject is a male or non-pregnant, non-lactating female, at least 6 weeks postpartum prior to screening visit. A urine pregnancy test is required for all female subjects unless she is not of childbearing potential, defined as postmenopausal for at least one year prior to screening visit or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy).
  • If female is of childbearing potential, is practicing one of the following methods of birth control (and will continue through the duration of the study):
  • Condoms, sponge, diaphragm, or intrauterine device;
  • Oral or parenteral contraceptives for 3 months prior to screening visit;
  • Vasectomized partner;
  • Total abstinence from sexual intercourse
  • Subject is able to speak, read and write in English
  • Subject has a Glooko compatible smartphone/device with an active data plan or access to Wi-Fi and downloaded at least one mobile application on their phone on their own.
  • Subject has performed self-monitoring of blood glucose at least five (5) times within two (2) weeks prior to screening visit.

Exclusion criteria

  • Subject has type 1 diabetes.
  • Subject has advanced disease (physical or psychological) that would prevent them from being able to comply with study tasks and considered exclusionary by the study physicians.
  • Subject has been on medication or therapy within the last 2 months that severely affects blood glucose levels (e.g. corticosteroids).
  • Subject has visual impairment which severely limits his/her ability to see or use the mobile application.
  • Subject is a participant in another clinical study that has not been approved as a concomitant study by Glooko.

Treatment and study plan

Glooko's mobile application

Device

Standard of care and Remote monitoring

Other names: Glooko's Population Tracker, Meter Sync Blue

Primary outcomes

  1. Change in HbA1c from baseline

    Time frame: 24 weeks

    Change in HbA1c from baseline

Secondary outcomes

  1. Change in HbA1c from baseline

    Time frame: 12 weeks

    Change in HbA1c from baseline

  2. Percentage of patients achieving </=7%

    Time frame: 12 and 24 weeks

    Percentage of patients achieving </=7%

  3. Basal insulin dose(Change from baseline)

    Time frame: 12 and 24 weeks

    Basal insulin dose(Change from baseline)

  4. Bolus insulin dose(Change from baseline)

    Time frame: 12 and 24 weeks

    Bolus insulin dose(Change from baseline)

  5. Change in Total insulin dose(Change from baseline)

    Time frame: 12 and 24 weeks

    Change in Total insulin dose(Change from baseline)

  6. Weight(Change from baseline)

    Time frame: 12 and 24 weeks

    Weight(Change from baseline)

  7. Problem Areas in Diabetes score(Change from baseline)

    Time frame: 12 and 24 weeks

    Problem Areas in Diabetes score(Change from baseline)

  8. Rate of hypoglycemic events (blood glucose level <70mg/dL)

    Time frame: 12 and 24 weeks

    Rate of hypoglycemic events (blood glucose level <70mg/dL)

  9. Self-monitoring blood glucose frequency

    Time frame: 12 and 24 weeks

    Self-monitoring blood glucose frequency

  10. Mean blood glucose concentration(Change from baseline)

    Time frame: 12 and 24 weeks

    Mean blood glucose concentration(Change from baseline)

  11. Number of ER visits(Change from baseline)

    Time frame: 12 and 24 weeks

    Number of ER visits(Change from baseline)

  12. Number of hospitalizations(Change from baseline)

    Time frame: 12 and 24 weeks

    Number of hospitalizations(Change from baseline)

Sponsors and collaborators

Lead sponsor

Glooko

Industry

Registry information

Official study title

The Glooko Diabetes Mobile Monitoring and Management Advantage Study

Important dates

Study start
2017
Primary completion
2020
Study completion
2020
First posted
Nov 28, 2016
Registry last updated
Jun 3, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.